Biopharma · FDA Approvals · Stock

HOWL Werewolf Therapeutics

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimu…

Assets on file: neridronate, WTX-124

Start live analysis of HOWL Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for HOWL, including recently decided ones.

December 2027

Dec 2027

~ Dec 2027

HOWLWerewolf Therapeutics

neridronate: Phase 3 trial NCT07210515 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

August 2028

Aug 2028

~ Aug 2028

HOWLWerewolf Therapeutics

WTX-124: Phase 1/Phase 2 trial NCT06939283 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for HOWL, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 29, 2026

03:23 PM

HOWLWerewolf Therapeutics

neridronate · NCT07210515 registry update

countries: {'total_sites': 31, 'us_sites': 31} → {'total_sites': 33, 'us_sites': 33}

Trial registry changeClinicalTrials.gov

Oct 19, 2026

03:23 PM

HOWLWerewolf Therapeutics

WTX-124 · NCT06939283 registry update

status: ACTIVE_NOT_RECRUITING → COMPLETED; primary_completion: 2028-08 → 2026-04-23; completion: 2028-08 → 2026-04-23; enrollment: 100 → 24

Trial registry changeClinicalTrials.gov Open record

Oct 16, 2026

03:22 PM

HOWLWerewolf Therapeutics

neridronate · NCT07210515 registry update

countries: {'total_sites': 27, 'us_sites': 27} → {'total_sites': 31, 'us_sites': 31}

Trial registry changeClinicalTrials.gov

Aug 21, 2026

01:10 PM

HOWLWerewolf Therapeutics

HOWL/Ambros announce merger + $150M placement to fund neridronate Phase 3

Werewolf Therapeutics and Ambros Therapeutics signed a definitive all-stock merger agreement that will create a Nasdaq-listed entity focused on neridronate for CRPS-1. A concurrent oversubscribed $150 million private placement will fund the ongoing pivotal CRPS-RISE Phase 3 trial through topline readout in 2028 and planned NDA submission, with cash runway into 1H 2029.

OtherSEC 8-K Open record

Dec 18, 2025

01:24 PM

HOWLWerewolf Therapeutics

HOWL: WTX-124 Phase 1/1b data update and INDs for WTX-1011/WTX-2022 guided for 1H26 and mid-2027

Corporate presentation outlines upcoming catalysts: final Phase 1/1b data for WTX-124 and Phase 1b/2 update for WTX-330 both expected in 1H26. IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) are guided for mid-2027. Company is seeking strategic partners for further development of both WTX-124 and WTX-330.

Conference presentationSEC 8-K